Takeda Pharmaceutical Co Ltd - Company Profile
Powered by 
All the data and insights you need on Takeda Pharmaceutical Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Takeda Pharmaceutical Co Ltd Strategy Report
- Understand Takeda Pharmaceutical Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Takeda Pharmaceutical Co Ltd (Takeda) is a research-based pharmaceutical company, which focuses on the discovery, development, manufacturing, marketing, commercialization, import and export of drugs. It provides treatment for inflammatory bowel disease, acid-related diseases, motility disorders and liver diseases; hemophilia and hereditary bleeding disorders; primary immunodeficiency and multifocal motor neuropathy; major depressive disorder and attention-deficit hyperactivity disorder; and its cancer treatment encompasses multiple myeloma, mantle cell lymphoma, non-small cell lung cancer and chronic myeloid leukemia. It markets products directly and through a network of wholesale distributors, retail chains and other purchasing groups worldwide. Takeda has partnership with academic institutions, small biotech, and large pharmaceutical companies. It has presence in the Americas, Europe, and Asia, among others. Takeda is headquartered in Tokyo, Japan.
Headquarters
Japan
Address
4f, 2-1-1, Nihombashihon-Cho, Chuo-Ku, Tokyo, 103-8668
Website
www.takeda.com
Telephone
81 3 32782111
No of Employees
49,095
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4502 (TYO)
Revenue (2023)
$29.8B
12.8%
(2023 vs 2022)
EPS
XYZ
Net Income (2023)
XYZ
37.8%
(2023 vs 2022)
Market Cap*
$44.5B
Net Profit Margin (2023)
XYZ
22.0%
(2023 vs 2022)
* As of and is in US$
Takeda Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Therapy Areas: | Actos |
| Oncology | Blopress |
| Gastroenterology | Takepron |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In November, the company secured an approval from the European Commission for TAKHZYRO (lanadelumab) for the routine prevention of recurrent attacks of Hereditary Angioedema (HAE) in patients aged 2 years and older. |
| 2023 | Regulatory Approval | In November, the company secured approval from the US Food and Drug Administration for its Fruzaqla (fruquintinib) for patients with metastatic colorectal cancer (mCRC) who have undergone previous treatment. |
| 2023 | Contracts/Agreements | In October, the company announced an alliance with the Mark Foundation for Cancer Research to accelerate the discovery and development of novel treatments for cancer. |
Competitor Comparison
| Key Parameters | Takeda Pharmaceutical Co Ltd | Pfizer Inc | F. Hoffmann-La Roche Ltd | Merck & Co Inc | AbbVie Inc |
|---|---|---|---|---|---|
| Headquarters | Japan | United States of America | Switzerland | United States of America | United States of America |
| City | Chuo-Ku | New York | Basel | Kenilworth | North Chicago |
| State/Province | Tokyo | New York | - | New Jersey | Illinois |
| No. of Employees | 49,095 | 83,000 | 103,613 | 69,000 | 50,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Christophe Weber | Director; President; Chief Executive Officer | Executive Board | 2015 | 57 |
| Costa Saroukos | Director; Chief Financial Officer | Executive Board | 2018 | 52 |
| Takako Ohyabu | Chief Global Corporate Affairs Officer | Senior Management | 2019 | 44 |
| Gabriele Ricci | Chief Data and Technology Officer | Senior Management | 2022 | 45 |
| Mwana Lugogo | Chief Ethics & Compliance Officer | Senior Management | 2019 | 53 |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward